Hepatitis C

Canadian Journal of Gastroenterology

Volumn 14, Issue SUPPL. B, 2000, Pages

  Lavanchy, Daniel ^a   Gavinio, Pilar ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Hepatitis C; Hepatitis C virus prevention; Public health; Review

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT;

BLOOD TRANSFUSION; DISEASE TRANSMISSION; HEALTH; HEPATITIS C; HUMAN; PREVALENCE; PRIMARY PREVENTION; PUBLIC HEALTH; REVIEW;

ANTIVIRAL AGENTS; BLOOD TRANSFUSION; HEPATITIS C; HUMANS; INTERFERON-ALPHA; PREVALENCE; PRIMARY PREVENTION; PUBLIC HEALTH; WORLD HEALTH;

EID: 0034223044     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2000/630301     Document Type: Article

References (111)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
2. WHO. Global surveillance and control of hepatitis C. J Med Virol 1999;6:35-47.
3. Lapane KL, Jakiche AF, Sugano D, Weng CS, Carey WD. Hepatitis C infection risk analysis: who should be screened? Comparison of multiple screening strategies based on the National Hepatitis Surveillance Program. Am J Gastroenterol 1998;93:591-6.
4. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999;30:956-61.
5. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992;27:1899-905.
6. Esteban JI, Lopez-Talavera JC, Genesca J, et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991;115:443-9.
7. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906-11.
8. Shakil AO, Conry-Cantilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995;123:330-7.
9. Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K. The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology 1996;23:695-9.
10. Poynard T, Bedossa P, Opoton P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
11. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-33.
12. Fujimura Y, Ishimoto S, Shimoyama T, et al. Genotypes and multiple infections with hepatitis C virus in patients with haemophilia A in Japan. J Viral Hepatol 1996;3:79-84.
13. Matsubara T, Sumazaki R, Shin K, Nagai Y, Takita H. Genotyping of hepatitis C virus: coinfection by multiple genotypes detected in children with chronic posttransfusion hepatitis C. J Pediatr Gastroenterol Nutr 1996;22:79-84.
14. Lai ME, Mazzoleni AP, Argiolu F, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994;43:388-90.
15. Farci P, Shimoda A, Wong D, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 1996;93:15394-9.
16. Farci P, Orgiana G, Purcell RH. Immunity elicited by hepatitis C virus. Clin Exp Rheumatol 1995;13(Suppl 13):S9-12.
17. Dhir V, Mohandas KM. Epidemiology of digestive tract cancers in India. III. Liver. Ind J Gastroenterol 1998;17:100-3.
18. Lee DS, Huh K, Lee EH, Lee DH, Hong KS, Sung YC. HCV and HBV coexist in HBsAg-negative patients with HCV viraemia: possibility of coinfection in these patients must be considered in HBV-high endemic area. J Gastroenterol Hepatol 1997;12:855-61.
19. Abdul Mujeeb S, Jamal Q, Khanani R, Iqbal N, Kaher S. Prevalence of hepatitis B surface antigen and HCV antibodies in hepatocellular carcinoma cases in Karachi, Pakistan. Trop Doct 1997;27:45-6.
20. Hwang SJ, Tong MJ, Lai PP, et al. Evaluation of hepatitis B and C viral markers: clinical significance in Asian and Caucasian patients with hepatocellular carcinoma in the United States of America. J Gastroenterol Hepatol 1996;11:949-54.
21. Yuan JM, Govindarajan S, Henderson BE, Yu MC. Low prevalence of hepatitis C infection in hepatocellular carcinoma (HCC) cases and population controls in Guangxi, a hyperendemic region for HCC in the People's Republic of China. Br J Cancer 1996;74:491-3.
22. Sallie R, Di Bisceglie AM. Viral hepatitis and hepatocellular carcinoma. Gastroenterol Clin North Am 1994;23:567-79.
23. Chang MH, Lee CY, Chen DS. Minimal role of hepatitis C virus infection in childhood liver diseases in an area hyperendemic for hepatitis B infection. J Med Virol 1993;40:322-5.
24. Mets T, Smitz J, Ngendahayo P, Sabbe L, Bigilimana I, Ngirabatware B. Hepatitis C virus infection in African patients with liver cirrhosis or primary hepatocellular carcinoma. Scand J Gastroenterol 1993;28:331-4.
25. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, et al. High prevalence of infection with hepatitis B and C viruses in patients with hepatocellular carcinoma in Japan. Hepatogastroenterology 1999;46:357-9.
26. Nishioka K, Watanabe J, Furuta S, et al. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 1991;67:429-33.
27. Levrero M, Tagger A, Balsano C, et al. Antibodies to hepatitis C virus in patients with hepatocellular carcinoma. J Hepatol 1991;12:60-3.
28. Munoz G, Velasco M, Thiers V, et al. Prevalencia y genotipos del virus de la hepatitis C en donantes de sangre y en pacientes con enfermedad hepática crónica y hepatocarcinoma en población Chilena. Rev Med Chil 1998;126:1035-42.
29. Goeser T, Muller HM, Solbach C, Toex U, Kommerell B, Theilmann L. Hepatitis C virus, alcoholic cirrhosis, and hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 1994;3:311-5.
30. Chuang WL, Chang WY, Lu SN, et al. The role of hepatitis C virus in chronic hepatitis B virus infection. Gastroenterol Jpn 1993;28(Suppl 5):23-7.
31. Resnick RH, Koff R. Hepatitis C-related hepatocellular carcinoma. Prevalence and significance. Arch Intern Med 1993;153:1672-7.
32. Yu MW, Chen CJ. Hepatitis B and C viruses in the development of hepatocellular carcinoma. Crit Rev Oncol Hematol 1994;17:71-91.
33. Castells L, Vargas V, Gonzalez A, Esteban J, Esteban R, Guardia J. Long interval between HCV infection and development of hepatocellular carcinoma. Liver 1995;15:159-63.
34. Bellentani S, Pozzato G, Saccoccio G, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 1999;44:874-80.
35. Koff RS, Dienstag JL. Extrahepatic manifestations of hepatitis C and the association with alcoholic liver disease. Semin Liver Dis 1995;15:101-9.
36. Couroucé AM. Development of screening and confirmation tests for antibodies to hepatitis C virus. Curr Stud Hematol Blood Transfus 1998;62:64-75.
37. Schiff ER, de Medina M, Kahn RS. New perspectives in the diagnosis of hepatitis C. Semin Liver Dis 1999;19(Suppl 1):3-15.
38. Allain JP. The status of hepatitis C virus screening. Transfus Med Rev 1998;12:46-55.
39. Simmonds P, Alberti A, Alter HJ, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994;19:1321-4.
40. Smith DB, Mellor J, Jarvis LM, et al. Variation of the hepatitis C virus 5' non-coding region: implications for secondary structure, virus detection and typing. The International HCV Collaborative Study Group. J Gen Virol 1995;76:1749-61.
41. Bukh J, Purcell RH, Miller RH. At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative El gene of isolates collected worldwide. Proc Natl Acad Sci USA 1993;90:8234-8.
42. McOmish F, Yap PL, Dow BC, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994;32:884-92.
43. Davidson F, Simmonds P, Ferguson JC, et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′ non-coding region. J Gen Virol 1995;76:1197-204.
44. Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens O. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996;34:2259-66.
45. Tokita H, Okamoto H, Tsuda F, et al. Hepatitis C virus variants from Vietnam are classifiable into the seventh, eighth, and ninth major genetic groups. Proc Natl Acad Sci USA 1994;91:11022-6.
46. Tokita H, Shrestha SM, Okamoto H, et al. Hepatitis C virus variants from Nepal with novel genotypes and their classification into the third major group. J Gen Virol 1994;75:931-6.
47. Tokita H, Okamoto H, Luengrojanakul P, et al. Hepatitis C virus variants from Thailand classifiable into five novel genotypes in the sixth (6b), seventh (7c, 7d) and ninth (9b, 9c) major genetic groups. J Gen Virol 1995;76:2329-35.
48. Ruggieri A, Argentini C, Kouruma F, et al. Heterogeneity of hepatitis C virus genotype 2 variants in West Central Africa (Guinea Conakry). J Gen Virol 1996;77:2073-6.
49. Stuyver L, van Arnhem W, Wyseur A, Hernandez F, Delaporte E, Maertens G. Classification of hepatitis C viruses based on phylogenetic analysis of the envelope 1 and nonstructural 5B regions and identification of five additional subtypes. Proc Natl Acad Sci USA 1994;91:10134-8.
50. Mellor J, Holmes EC, Jarvis LM, Yap PL, Simmonds P. Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: implications for virus classification. The International HCV Collaborative Study Group. J Gen Virol 1995;76:2493-507.
51. Mellor J, Walsh EA, Prescott LE, et al. Survey of type 6 group variants of hepatitis C virus in Southeast Asia by using a core-based genotyping assay. J Clin Microbiol 1996;34:417-23.
52. Di Bisceglie AM, Order SE, Klein JL, et al. The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. Am J Gastroenterol 1991;86:335-8.
53. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
54. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-5.
55. Verbaan H, Hoffmann G, Lindgren S, Nilsson S, Widell A, Eriksson S. Long-term outcome of chronic hepatitis C infection in a low-prevalence area. Scand J Gastroenterol 1998;33:650-5.
56. WHO. Hepatitis C. Weekly Epidemiological Record 1997;72:65-9.
57. WHO. Hepatitis C: Global Prevalence. Weekly Epidemiological Record 1997;72:341-4.
58. Crofts N, Jolley D, Kaldor J, van Beek I, Wodak A. Epidemiology of hepatitis C virus infection among injecting drug users in Australia. J Epidemiol Community Health 1997;51:692-7.
59. Alter MJ, Hadler SC, Judson FN, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990;264:2231-5.
60. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26:62S-5S.
61. Delage G, Infante-Rivard C, Chiavetta JA, Willems B, Pi D, Fast M. Risk factors for acquisition of hepatitis C virus infection in blood donors: results of a case-control study. Gastroenterology 1999;116:893-9.
62. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 1998;47:1-39.
63. Mansell CJ, Locarnini SA. Epidemiology of hepatitis C in the East. Semin Liver Dis 1995;15:15-32.
64. Aach RD, Stevens CE, Hollinger FB, et al. Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays. N Engl J Med 1991;325:1325-9.
65. Wang JT, Wang TH, Lin JT, Sheu JC, Sung JL, Chen DS. Hepatitis C virus in a prospective study of posttransfusion non-A, non- B hepatitis in Taiwan. J Med Virol 1990;32:83-6.
66. Donahue JG, Nelson KE, Munoz A, et al. Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. Am J Epidemiol 1991;134:1206-11.
67. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N Engl J Med 1996;34:1685-90.
68. Suzuki K, Mizokami M, Lau JY, et al. Confirmation of hepatitis C virus transmission through needlestick accidents by molecular evolutionary analysis. J Infect Dis 1994;170:1575-8.
69. Schvarcz R, Johansson B, Nystrom B, Sonnerborg A. Nosocomial transmission of hepatitis C virus. Infection 1997;25:74-7.
70. Quinti I, Renganathan E, El Ghazzawi E, et al. Seroprevalence of HIV and HCV infections in Alexandria, Egypt. Zentralbl Bakteriol 1995;283:239-44.
71. Kiyosawa K, Tanaka E, Sodeyama T, et al. Transmission of hepatitis C in an isolated area in Japan: community-acquired infection. The South Kiso Hepatitis Study Group. Gastroenterology 1994;106:1596-602.
72. Frank C, Mohamed M, Strickland T, et al. The role of parental antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000;355:887-91.
73. World Health Organization. Two simple ways to use less vaccines. EPI Update 30 1996;96:10825
74. Hamid SS, Farooqui B, Rizvi Q, Sultana T, Siddiqui AA. Risk of transmission and features of hepatitis C after needlestick injuries. Infect Control Hosp Epidemiol 1999;20:63-4.
75. Takagi H, Uehara M, Kakizaki S, et al. Accidental transmission of HCV and treatment with interferon. J Gastroenterol Hepatol 1998;13:238-43.
76. Mujeeb SA, Khatri Y, Khanani R. Frequency of parenteral exposure and seroprevalence of HBV, HCV, and HIV among operation room personnel. J Hosp Infect 1998;38:133-7.
77. Kaufmann M, Bode JC. HCV-Infektionsrisiko in medizinischen Berufen. Versicherungsmedizin 1997;49:132-4.
78. Hofmann F, Michaelis M, Rieger MA, Hasselhom HM, Berthold H. Zur arbeitsmedizinischen Bedeutung der Hepatitis C bei Beschäftigten im Gesundheitsdienst. Gesundheitswesen 1997;59:452-60.
79. Mizuno Y, Suzuki K, Mori M, et al. Study of needlestick accidents and hepatitis C virus infection in healthcare workers by molecular evolutionary analysis. J Hosp Infect 1997;35:149-54.
80. Lanphear BP, Linnemann CCJr, Cannon CG, DeRonde MM, Pendy L, Kerley LM. Hepatitis C virus infection in healthcare workers: risk of exposure and infection. Infect Control Hosp Epidemiol 1994;15:745-50.
81. Hepatitis C virus transmission from health care worker to patient. Commun Dis Rep CDR Wkly 1995;5:121.
82. Bruguera M. La transmisión de la hepatitis viral del médico al paciente, una circunstancia excepcional. Med Clin (Barc) 1997;108:537-8.
83. Gerberding JL. The infected health care provider. N Engl J Med 1996;334:594-5.
84. Donahue JG, Munoz A, Ness PM, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992;327:369-73.
85. Mele A, Sagliocca L, Manzillo G, et al. Risk factors for acute non-A, non-B hepatitis and their relationship to antibodies for hepatitis C virus: a case-control study. Am J Public Health 1994;84:1640-3.
86. Alter MJ, Gerety RJ, Smallwood LA, et al. Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population. J Infect Dis 1982;145:886-93.
87. Alter MJ, Coleman PJ, Alexander WJ, et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA 1989;262:1201-5.
88. Camma C, Almasio P, Craxi A. Interferon as treatment for acute hepatitis C. A meta-analysis. Dig Dis Sci 1996;41:1248-55.
89. Oketani M, Higashi T, Yamasaki N, Shinmyozu K, Osame M, Arima T. Complete response to twice-a-day interferon-beta with standard interferon-alpha therapy in acute hepatitis C after a needlestick. J Clin Gastroenterol 1999;28:49-51.
90. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691-6.
91. Everhart JE, Di Bisceglie AM, Murray LM, et al. Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers. Ann Intern Med 1990;112:544-5.
92. Gordon SC, Patel AH, Kulesza GW, Barnes RE, Silverman AL. Lack of evidence for the heterosexual transmission of hepatitis C. Am J Gastroenterol 1992;87:1849-51.
93. Tong MJ, Lai PPC, Hwang S-J. Evaluation of sexual transmission in patients with hepatitis C infection. Clin Virol Diagn 1995;3:39-47.
94. Westh H, Worm AM, Jensen BL, et al. Hepatitis C virus antibodies in homosexual men and intravenous drug users in Denmark. Infection 1993;21:115-7.
95. Marcellin P, Colin JF, Martinot-Peignoux M, et al. Hepatitis C virus infection in anti-HIV positive and negative French homosexual men with chronic hepatitis: comparison of second- and third-generation anti-HCV testing. Liver 1993;13:319-22.
96. Tor J, Llibre JM, Carbonell M, et al. Sexual transmission of hepatitis C virus and its relation with hepatitis B virus and HIV. Br Med J 1990;301:1130-3.
97. Thomas DL, Villano SA, Riester KA, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study. J Infect Dis 1998;177:1480-8.
98. Resti M, Azzari C, Lega L, et al. Mother-to-infant transmission of hepatitis C virus. Acta Paediatr 1995;84:251-5.
99. Manzini P, Saracco G, Cerchier A, et al. Human immunodeficiency virus infection as risk factor for mother-to-child hepatitis C virus transmission; persistence of anti-hepatitis C virus in children is associated with the mother's anti-hepatitis C virus immunoblotting pattern. Hepatology 1995;21:328-32.
100. Zanetti AR, Tanzi E, Paccagnini S, et al. Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet 1995;345:289-91.
101. Paccagnini S, Principi N, Massironi E, et al. Perinatal transmission and manifestation of hepatitis C virus infection in a high risk population. Pediatr Infect Dis J 1995;14:195-9.
102. Lin HH, Kao JH, Hsu HY, et al. Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers. J Pediatr 1995;126:589-91.
103. Ohto H, Okamoto H, Mishira S. Vertical transmission of hepatitis C virus. Lancet 1994;331:400.
104. Management of hepatitis C. NIH consensus statement. 1997:15:1-41.
105. Schalm SW, Weiland O, Hansen BE, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Gastroenterology 1999;117:408-13.
106. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-32.
107. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
108. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999;19(Suppl 1):57-65.
109. Hoofnagle JH, di Bisceglie AM. Drug Therapy: The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-56.
110. World Health Organization. Ports designated in application of the International Health Regulations. Wkly Epidemiol Rep 1999;74:425-7.
111. World Health Organization. Global prevalence (update). Wkly Epidemiol Rep 2000;75:18-9.